| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000021494 |
| Receipt No. | R000024724 |
| Scientific Title | Comparison of lipid lowering effect of anagliptin and miglitol in patients with type 2 diabetes |
| Date of disclosure of the study information | 2016/03/28 |
| Last modified on | 2019/03/27 (Ver. 3) |
| Basic information | ||
| Public title | Comparison of lipid lowering effect of anagliptin and miglitol in patients with type 2 diabetes | |
| Acronym | Comparison of lipid lowering effect of anagliptin and miglitol | |
| Scientific Title | Comparison of lipid lowering effect of anagliptin and miglitol in patients with type 2 diabetes | |
| Scientific Title:Acronym | Comparison of lipid lowering effect of anagliptin and miglitol | |
| Region |
|
|
| Condition | ||
| Condition | Type 2 diabetes | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Comparison of lipid lowering effect ofanagliptin and miglitol in patients with type 2 diabtes |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Low-density lipoprotein cholesterol (LDL-C) |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Administration of anagliptin | |
| Interventions/Control_2 | Administration of miglitol | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with type 2 diabetes
LDL-C (120mg/dL and over) |
|||
| Key exclusion criteria | Patients treated with alpha glucosidase inhibitor, DPP-4 inhibitor, insulin, or glucagon like peptide-1receptor agonist.
Patients with sever liver and kidney disfunction. Patients with pregnacy. Patients with history of ileus. |
|||
| Target sample size | 60 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Yokohama City University Hospital | ||||||
| Division name | Department of Endocrinology and Metabolism | ||||||
| Zip code | |||||||
| Address | Fuku-ura 3-9, Kanazawa-ku, Yokohama | ||||||
| TEL | 045-787-2639 | ||||||
| aokikazu@yokohama-cu.ac.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Yokohama City University | ||||||
| Division name | Department of Endocrinology and Metabolism | ||||||
| Zip code | |||||||
| Address | Fuku-ura 3-9, Kanazawa-ku, Yokohama | ||||||
| TEL | 045-787-2639 | ||||||
| Homepage URL | |||||||
| shibatae15@gmail.com | |||||||
| Sponsor | |
| Institute | Yokohama City University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Sanwa Kagaku Kenkyusho Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024724 |